@FiercePharma: Regulatory challenges top of mind at inaugural ACI animal health forum. FierceAnimalHealth story | Follow @FiercePharma
@EricPFierce: ICYMI: Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. More | Follow @EricPFierce
@CarlyHFierce: ICYMI: Boehringer's Ofev, chasing a Roche rival, wins backing from NICE. Story | Follow @CarlyHFierce
> Sanofi ($SNY) raised €2 billion ($2.25 billion) in a bond sale to fund operations and pay down existing debt. Release
> Hungarian regulators fined three drug companies 792.2 million forints ($2.87 million) each for acting as a cartel on a public tender by the Budapest Healthcare Centre. Story
> Some doctors are cautioning against using Sprout Pharmaceuticals' controversial female libido drug, Addyi. Article
> Bayer appointed Natalie Bartner, Sanofi's former VP head of commercial strategy, as president of its North America consumer care unit. Story
> A new report funded by Bristol-Myers Squibb ($BMY) shows that cancer deaths in the U.K. cost the country more than half a billion pounds a year. Article
Medical Device News
@FierceMedDev: Study: close management of blood pressure reduces cardiac disease, deaths. Article | Follow @FierceMedDev
@VarunSaxena2: UPDATED: FDA begs manufacturers to participate in global single audit pilot, says next stage may not be voluntary. More | Follow @VarunSaxena2
@EmilyWFierce: ICYMI: Advera Health Analytics: Merck statins linked to more muscle side effects than rest of class. Report | Follow @EmilyWFierce
> Olympus, Sony focus on JV with high-def endoscope launch. Report
> Med tech IPOs fall into place: Penumbra, Symetis, Novocure and Adesto. Story
> Philips, Salesforce develop diabetes app, system to marry consumer and medical data. Article
Biotech News
@FierceBiotech: Patrick Soon-Shiong plucks another cancer drug out of Amgen's pipeline. Story | Follow @FierceBiotech
@JohnCFierce: Lipstick on a pig: XenoPort plunges as investors sour fast on "positive" psoriasis data. Article | Follow @JohnCFierce
@DamianFierce: Reminder that $NVO is risking billions of dollars on Tresiba data that management ~hasn't actually seen~. More from Reuters | Follow @DamianFierce
> Amicus plots an end-of-year FDA filing for its resuscitated lead drug. Report
> Celgene antes up $25M for first seat at antibody engineers' new deal table. Story
> GW sees a future in schizophrenia with its cannabis-based pipeline. Article
Drug Delivery News
> Novo, MIT's Langer Lab announce research alliance aimed at creating novel drug delivery devices. More
> Gene delivery player to go public this week, aiming to raise $100M. Item
> U.S.-Irish collaboration picks up $4.4M in pursuit of pancreatic cancer nanomeds. Report
> New surface protein found on cancer cells offers specific drug targeting, could spare fertility. Story
> Study finds ultrasound contrast agents can improve delivery of chemotherapy drugs. Article
Pharma Manufacturing News
> Abbott run-in with Indian regulators illustrates India's shortcomings: Reuters. More
> Endo's Qualitest recalls blood pressure, gout drugs. News
> California law requires drug info in 6 languages. Item
> U.K.'s Abzena shells out $8.4M for San Diego-based CDMO. Story
> FDA bans India's Polydrug plant, following actions by EMA and Canada. Article
Pharma Asia News
> China plans public health push on cancer, wants to expand screening. Report
> Japan's Eisai to present papers on Lenvima clinical data at European Cancer Congress. More
> Takeda crosses Actos settlement threshold as 96% of plaintiffs seek resolution. Story
> China plans medical exchange league with Arab states. Item
> Indian generics bid to challenge Gilead's Sovaldi patent dropped. Article
And Finally… A panel of U.S. medical experts is recommending daily low-dose aspirin for adults between ages 50 and 59 who have increased risk of heart disease and stroke. Story